Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Empliciti Generic Name & Formulations
Legal Class
Rx
General Description
Elotuzumab 300mg, 400mg; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Pharmacological Class
SLAMF7-directed immunostimulatory antibody.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Empliciti Indications
Indications
Treatment of multiple myeloma: in combination with lenalidomide and dexamethasone in patients who have received 1–3 prior therapies; or in combination with pomalidomide and dexamethasone in patients who have received ≥2 prior therapies including lenalidomide and a proteasome inhibitor.
Empliciti Dosage and Administration
Adult
Give by IV infusion at initial rate of 0.5mL/min (10mg/kg dose) or 3mL/min (20mg/kg dose); may increase stepwise if no reactions develop (see full labeling); max rate 5mL/min. In combination with lenalidomide and dexamethasone: 10mg/kg every week for the first 2 cycles then every 2 weeks thereafter. In combination with pomalidomide and dexamethasone: 10mg/kg every week for first 2 cycles; then starting at cycle 3, give 20mg/kg every 4 weeks. Both: continue until disease progression or unacceptable toxicity. For dosing schedule of lenalidomide, pomalidomide, and dexamethasone: see full labeling. Premedicate with dexamethasone, H1 blocker, H2 blocker, and acetaminophen before each infusion. Dose modifications: see full labeling.
Children
Not established.
Empliciti Contraindications
Contraindications
Consult lenalidomide, pomalidomide, and dexamethasone prescribing information for contraindications before starting therapy (eg, pregnancy).
Empliciti Boxed Warnings
Not Applicable
Empliciti Warnings/Precautions
Warnings/Precautions
Interrupt infusion if Grade ≥2 infusion reactions occur and manage appropriately. Monitor for development of infections and treat promptly. Monitor for second primary malignancies. Monitor liver function periodically; discontinue if Grade ≥3 elevation of liver enzymes occur; consider resuming after return to baseline values. Pregnancy: not studied. Nursing mothers: not recommended.
Empliciti Pharmacokinetics
See Literature
Empliciti Interactions
Interactions
May interfere with correct response classification in SPEP and serum immunofixation assays.
Empliciti Adverse Reactions
Adverse Reactions
Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, hyperglycemia.
Empliciti Clinical Trials
See Literature
Empliciti Note
Notes
For lenalidomide, pomalidomide, and dexamethasone specific dosing and safety information, refer to their respective full labeling.
Empliciti Patient Counseling
See Literature
Images
